Plenary Lecture at SABCS: Researchers Continue to Explore HER2 Blockade Strategies

Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues, said Mothaffer Rimawi, MD, of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX. In a plenary lecture, Dr Rimawi reviewed HER2 therapies for curative intent over the past decade.

Videos

Perspectives on the Collaborative Management of HER2-Positive Breast Cancer

Advertisement

In The News

The ASCO Post

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care

MedicalXpress

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

OncLive

Age and Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer

OncLive

Neoadjuvant Therapy Fundamental in Triple-Negative and HER2-Positive Breast Cancer

BreastCancer.org

Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease

View all >

In The Literature

JAMA Oncol

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

Eur J Cancer

Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status

BMJ Open

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

JAMA Oncol

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study

BMC Cancer

Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells

View all >